Anti-platelet therapy and managing ulcer risk

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 2, 2012, Pages 195-199

  Chan, Francis K L ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Aspirin; Clopidgrel; Proton pump inhibitor; Ulcer bleeding

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYTOCHROME P450 2C; DRUG METABOLITE; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ACUTE CORONARY SYNDROME; ALCOHOLISM; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR RISK; CORONARY STENT; DIABETES MELLITUS; DRUG TOLERABILITY; GENETIC POLYMORPHISM; HEART ATRIUM FIBRILLATION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; KIDNEY FAILURE; LOSS OF FUNCTION MUTATION; META ANALYSIS (TOPIC); PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK REDUCTION; THROMBOEMBOLISM; UPPER GASTROINTESTINAL BLEEDING;

EID: 84856159490     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.07029.x     Document Type: Article

References (33)

1. Taha AS, Angerson WJ, Knill-Jones RP, Blatchford O. Upper gastrointestinal haemorrhage associated with low-dose aspirin and anti-thrombotic drugs-a 6-year analysis and comparison with non-steroidal anti-inflammatory drugs. Aliment. Pharmacol. Ther. 2005; 22: 285-9.
2. Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sáinz R. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment. Pharmacol. Ther. 2002; 16: 779-86.
3. Chan FK. Review: low-dose aspirin causes a small increase in gastrointestinal bleeding. ACP J. Club 2007; 146: 13.
4. Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet 2009; 374: 1449-61.
5. Moukarbel GV, Signorovitch JE, Pfeffer MA etal. Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. Eur. Heart J. 2009; 30: 2226-32.
6. Chan FK, Chung SC, Suen BY etal. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N. Engl. J. Med. 2001; 344: 967-73.
7. Lai KC, Lam SK, Chu KM etal. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N. Engl. J. Med. 2002; 346: 2033-8.
8. Chan FK, Ching J, Sune BY etal. Effect of H. pylori eradication on the long-term incidence of recurrent ulcer bleeding in high-risk aspirin users: a 10-year prospective cohort study. Gastroenterology 2011; 140: S173-4.
9. Braunwald E, Antman EM, Beasley JW etal. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J. Am. Coll. Cardiol. 2002; 40: 1366-74.
10. Chan FK, Ching JY, Hung LC etal. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N. Engl. J. Med. 2005; 352: 238-44.
11. Bhatt DL, Scheiman J, Abraham NS etal. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J. Am. Coll. Cardiol. 2008; 52: 1502-17.
12. Yusuf S, Zhao F, Mehta SR etal. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 2001; 345: 494-502.
13. ACTIVE Investigators, Connolly SJ, Pogue J etal. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N. Engl. J. Med. 2009; 360: 2066-78.
14. Bhatt DL, Cryer BL, Contant CF etal. Clopidogrel with or without omeprazole in coronary artery disease. N. Engl. J. Med. 2010; 363: 1909-17.
15. Ng FH, Lam KF, Wong SY etal. Upper gastrointestinal bleeding in patients with aspirin and clopidogrel co-therapy. Digestion 2008; 77: 173-7.
16. Ho PM, Maddox TM, Wang L etal. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-44.
17. Wu CY, Chan FK, Wu MS etal. Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel. Gastroenterology 2010; 139: 1165-71.
18. Mega JL, Close SL, Wiviott SD etal. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 2009; 360: 354-62.
19. Gilard M, Arnaud B, Cornily JC etal. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J. Am. Coll. Cardiol. 2008; 51: 256-60.
20. Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab. Dispos. 2004; 32: 821-7.
21. Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment. Pharmacol. Ther. 2010; 31: 810-23.
22. US Food and Drug Administration. Updated Safety Information about a drug interaction between Clopidogrel Bisulfate (marketed as Plavix) and Omeprazole (marketed as Prilosec and Prilosec OTC). Cited 6 Nov 2011. Available from URL:.
23. European Medicines Agency. Public statement on possible interaction between clopidogrel and proton pump inhibitors. Cited 6 Nov 2011. Available from URL:.
24. Hulot J, Collet J, Silvain J etal. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration. J. Am. Coll. Cardiol. 2010; 56: 134-43.
25. Collet JP, Hulot JS, Pena A etal. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009; 373: 309-17.
26. Shuldiner AR, O'Connell JR, Bliden KP etal. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302: 849-57.
27. Yamada S, Onda M, Kato S etal. Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations. J. Gastroenterol. 2001; 36: 669-72.
28. Lee VW, Chau TS, Chan AK etal. Pharmacogenetics of esomeprazole or rabeprazole-based triple therapy in Helicobacter pylori eradication in Hong Kong non-ulcer dyspepsia Chinese subjects. J. Clin. Pharm. Ther. 2010; 35: 343-50.
29. Simon T, Steg PG, Gilard M etal. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation 2011; 123: 474-82.
30. Becker RC, Scheiman J, Dauerman HL etal. Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures. J. Am. Coll. Cardiol. 2009; 54: 2261-76.
31. Cuisset T, Quilici J, Cohen W etal. Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndrome. Am. J. Cardiol. 2011; 108: 760-5.
32. Price MJ, Berger PB, Teirstein PS etal. Standard- versus high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011; 305: 1097-105.
33. Alexopoulos D, Xanthopoulou I, Davlouros P etal. Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150mg) clopidogrel. Am. Heart J. 2011; 162: 733-9.